Last reviewed · How we verify
Infusion of MSCs
At a glance
| Generic name | Infusion of MSCs |
|---|---|
| Sponsor | Joanne Kurtzberg, MD |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease (PHASE2)
- PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- Autologous Stem Cell Therapy in Patients With Multiple System Atrophy (PHASE2)
- PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM) (PHASE2)
- Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia (PHASE1, PHASE2)
- "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
- Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy in Group E COPD Patients (PHASE2)
- Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infusion of MSCs CI brief — competitive landscape report
- Infusion of MSCs updates RSS · CI watch RSS
- Joanne Kurtzberg, MD portfolio CI